Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Jul;27(3):363-401.
doi: 10.3350/cmh.2021.0178. Epub 2021 Jun 22.

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang  1 , Hye Won Lee  2 , Jeong-Ju Yoo  3 , Yuri Cho  4 , Seung Up Kim  2 , Tae Hee Lee  5 , Byoung Kuk Jang  6 , Sang Gyune Kim  7 , Sang Bong Ahn  7 , Haeryoung Kim  8 , Dae Won Jun  9 , Joon-Il Choi  10 , Do Seon Song  11 , Won Kim  12 , Soung Won Jeong  13 , Moon Young Kim  1 , Hong Koh  14 , Sujin Jeong  15 , Jin-Woo Lee  16 , Yong Kyun Cho  17 ; Korean Association for the Study of the Liver (KASL)
Affiliations
Practice Guideline

KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

Seong Hee Kang et al. Clin Mol Hepatol. 2021 Jul.
No abstract available

Keywords: Diagnosis; Epidemiology; Guideline; Non-alcoholic fatty liver disease; Treatment.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Yong Kyun Cho is a speaker for Samil Pharm, Bukwang and DaeWoong. He has received a research grant from DaeWoong, Dong-A, Celltrion and Ildong.

Seung Up Kim has served as an advisory committee member of Gilead Sciences, Bayer, Eisai, Novo Nordisk, and GreenCross. He is a speaker for Gilead Sciences, GSK, Bayer, Eisai, Abbvie, EchoSens, MSD, Eisai, Otsuka, Bristol-Myers Squibb, Yuhan, Samil Pharm, Ildong, Celltrion, PharmaKING, DaeWoong, Samjin, DongA, Hanmi, BuKwang, Echme medical, Hanwha, Sysmax, and ChongKunDang. He has also received a research grant from Abbvie, Bristol-Myers Squibb, ChongKunDang, DaeWoong, Hanmi, Samil Pharm, and Echme Medical.

Jeong-Ju Yoo is a speaker for DaeWoong, Ildong, Pharmaking, Dong-A, BMS, Samil Pharm and Bukwang.

Tae Hee Lee is a speaker for Abbvie, Gilead, Samil Pharm and Yuhan. He has received a research grant from Eisai, Celltrion, PharmaKING and GC Wellbeing.

Byoung Kuk Jang is a speaker for Gilead. He has received a research grant from PharmaKING, Novo Nordisk Pharma, Vaccitech and GC Wellbeing.

Sang Gyune Kim has received grants from GE healthcare, Samsung Medison, BMS, Samil, Ildong; received honoraria from BMS, MSD, Gilead, Daewoog, Hanwha; consulted Samsung Medison.

Sang Bong Ahn has received grants from Hanwha, Samjin, Ildong, and Hanmi.

Dae Won Jun has served as an advisory committee member of Sysmax, J2H, and Future medicine. He is a speaker for Gilead Sciences, Bristol-Myers Squibb, Yuhan, Chong Kun Dang, Ildong, Donga, Samil, Phamaking, Celltrion, and Daewoong. He has also received a research grant from Yuhan.

Joon-Il Choi previously received grants from Bayer Healthcare, Guerbet Korea, Bracco Korea and Samsung Medison. He previously received honorariums from Bayer Healthcare, Guerbet Korea and Bracco Korea.

Won Kim has served as an advisory committee member of Boehringer-Ingelheim, HK inno.N, GreenCross, Standigm, Pharmaking, KOBIOLABS, Eisai, Zydus and Novonordisk. He is a speaker for Gilead, Boehringer-Ingelheim, Samil, Il-dong, LG chemistry and Bukwang. He has also received a research grant from Gilead, Il-dong, GreenCross, Bukwang, Roche, Galmed, Novartis, Pfizer, Springbank, Altimmune, MSD, BMS, Novonordisk, Hitachi Aloka, JW medical, Dicerna and Enyo.

Soung Won Jeong is a speaker for Daewoong, Samil and Pharmaking. He has received a research grant from Dong-A ST, Ildong and Chongkundang.

Moon Young Kim is a speaker for Samjin and Gilead. He has received a research grant from Yuhan.

Jin-Woo Lee has served as an advisory committee member of Abbvie and Novo Nordisk. He has received a research grant from Galectin Therapeutics Inc, BMS, MSD and Ipsen.

The other authors declare that they have no competing interests.

Figures

Figure 1.
Figure 1.
Risk factors for nonalcoholic fatty liver disease.
Figure 2.
Figure 2.
Algorithm to differentiate advanced fibrosis. TE, transient elastography; FIB-4, fibrosis-4 index; NFS, nonalcoholic fatty liver disease fibrosis score.
See this image and copyright information in PMC

References

    1. European Association for the Study of the Liver (EASL) European Association for the Study of Diabetes (EASD) European Association for the Study of Obesity (EASO) EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9:65–90. - PMC - PubMed
    1. The Lancet Gastroenterology Hepatology Redefining non-alcoholic fatty liver disease: what’s in a name? Lancet Gastroenterol Hepatol. 2020;5:419. - PubMed
    1. Eslam M, Sanyal AJ, George J, International Consensus Panel MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999–2014. e1. - PubMed
    1. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53:686–692. - PubMed
    1. Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111:1133–1140. - PubMed

Publication types

MeSH terms